Novavax COVID-19 vaccine granted UK approval for 12- to 17-year-olds by MHRA

Children's Health

Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).

The approval follows a review of the safety, quality and effectiveness of the vaccine in this age group, and expert advice from the government’s independent scientific advisory body, the Commission on Human Medicines.

Dr June Raine, MHRA Chief Executive, said:

Following our review of the safety, quality and effectiveness of Nuvaxovid in 12- to 17-year-olds, I am pleased to confirm that that the vaccine has now been authorized in this age group. In reaching this decision, we have taken advice from the government’s independent scientific advisory body, the Commission on Human Medicines.”

The Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in Great Britain only and was approved via the European Commission (EC) Decision Reliance Route. This is when the marketing authorisation application made by the company references the decision made by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

Nuvaxovid is authorised in children aged 12-17 years in Northern Ireland under the CMA extension granted by the European Medicines Agency on 1 July 2022.

Products You May Like

Articles You May Like

Prenatal intervention benefits mothers’ mental health up to eight years later
Vaccination against E. coli could help prevent some forms of childhood malnutrition, stunting
New program lowers the risk of car crashes for teenagers with ADHD
MHRA authorizes the use of Pfizer/Biontech COVID-19 vaccine in kids aged 6 months to 4 years
Researchers examine hesitancy to use evidence-based treatment for childhood anxiety disorders

Leave a Reply

Your email address will not be published. Required fields are marked *